Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5419]
News [12588]
Articles [170]
Editorials [5]
Conferences [246]
elearning [17]
Investigational immunotherapy drug combo safe with early signs of effectiveness...
Dr David Bajor - University of Pennsylvania, Philadelphia, USA
Investigational immunotherapy drug combo safe with early signs of effectiveness in advanced melanoma ( Dr David Bajor - University of Pennsylvania, Philadelphia, USA )
29 Apr 2015
Pembrolizumab showed clinical benefit in malignant pleural mesothelioma
Dr Evan Alley - University of Pennsylvania, Philadelphia, USA
Pembrolizumab showed clinical benefit in malignant pleural mesothelioma ( Dr Evan Alley - University of Pennsylvania, Philadelphia, USA )
29 Apr 2015
Chk1 inhibition combined with standard dose gemcitabine may be safe and...
Dr Jeffrey Infante - Sarah Cannon Research Institute, Nashville, USA
Chk1 inhibition combined with standard dose gemcitabine may be safe and effective ( Dr Jeffrey Infante - Sarah Cannon Research Institute, Nashville, USA )
29 Apr 2015
Developing treatments for indolent non hodgkin lymphoma
Dr Andrew Davies and Dr Paul Fields
Developing treatments for indolent non hodgkin lymphoma ( Dr Andrew Davies and Dr Paul Fields )
29 Apr 2015
Latest trials and outcomes with new CLL treatments
Dr George Follows and Professor Peter Hillmen
Latest trials and outcomes with new CLL treatments ( Dr George Follows and Professor Peter Hillmen )
29 Apr 2015
Updated results on phase III CLL trial shows 90% response rate using ibrutinib
Dr Claire Dearden - Royal Marsden Hospital, London, UK
Updated results on phase III CLL trial shows 90% response rate using ibrutinib ( Dr Claire Dearden - Royal Marsden Hospital, London, UK )
29 Apr 2015
The evolution of CLL treatment
Prof Clemens Wendtner, Dr Francesc Bosch, Prof Paolo Ghia and Prof Florence...
The evolution of CLL treatment ( Prof Clemens Wendtner, Dr Francesc Bosch, Prof Paolo Ghia and Prof Florence Cymbalista )
28 Apr 2015
Investigational PD-L1–targeted immunotherapy safe for patients with triple...
Prof Leisha Emens - Johns Hopkins Kimmel Cancer Center, Baltimore, USA
Investigational PD-L1–targeted immunotherapy safe for patients with triple-negative breast cancer, effective in some ( Prof Leisha Emens - Johns Hopkins Kimmel Cancer Center, Baltimore, USA )
27 Apr 2015
US breast cancer cases expected to increase by as much as 50 percent by 2030
Dr Phillip Rosenberg - Division of Cancer Epidemiology and Genetics, National...
US breast cancer cases expected to increase by as much as 50 percent by 2030 ( Dr Phillip Rosenberg - Division of Cancer Epidemiology and Genetics, National Cancer Institute, USA )
27 Apr 2015
Phase II trial of ipilimumab-nivolumab combo shows promise in advanced melanoma
Dr Stephen Hodi - Dana-Farber Cancer Institute, Boston, USA
Phase II trial of ipilimumab-nivolumab combo shows promise in advanced melanoma ( Dr Stephen Hodi - Dana-Farber Cancer Institute, Boston, USA )
27 Apr 2015
New T cell–based immunotherapy shows promise for lethal stem cell transplant...
Dr Richard O'Reilly - Memorial Sloan Kettering Cancer Center, New York, USA
New T cell–based immunotherapy shows promise for lethal stem cell transplant complication ( Dr Richard O'Reilly - Memorial Sloan Kettering Cancer Center, New York, USA )
27 Apr 2015
Pembrolizumab promising for lung cancer, clinical outcomes correlate with...
Dr Edward Garon - David Geffen School of Medicine at the University of...
Pembrolizumab promising for lung cancer, clinical outcomes correlate with biomarker ( Dr Edward Garon - David Geffen School of Medicine at the University of California, Los Angeles, USA )
27 Apr 2015

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation